These results suggest that the upregulation of Bcl-xL via ERK reactivation is involved in the adaptive resistance of ALK-rearranged lung cancer cells, and that inhibition of the MEK/ERK pathway by combination therapy with lorlatinib and erlotinib induces apoptosis via suppression of Bcl-xL. Here, ALK is linked to lung carcinoma.